"Duloxin" is used for:
1 capsule contains 33.7 mg of duloxetine hydrochloride, which is equivalent to 30 mg duloxetine, or 67.4 mg of duloxetine hydrochloride, which is equivalent to 60 mg duloxetine.
Excipients: spherical sugar, hydroxypropyl methylcellulose, polyethylene glycol 6000, talc, sucrose, hydroxypropyl methylcellulose acetate succinate, triethyl citrate;
Hard gelatin capsule No. 3 (for capsules 30 mg)
The composition of the capsule shell: titanium dioxide (E 171), indigotine blue (E 132), gelatin;
Hard gelatin capsule No. 1 (for capsules 60 mg)
The composition of the capsule shell: titanium dioxide (E 171), indigotine blue (E 132), quinoline yellow (E 104), erythrosine red (E 127), gelatin.
Hypersensitivity to the active substance or to any of the excipients of the preparation.
It is taken orally.
Pregnancy
There are no corresponding data on the use of duloxetine in pregnant women.
Children
The safety and efficacy of duloxetine in children under 18 years of age has not been studied, therefore, this age category of patients should not be prescribed.
Drivers
Studies on the effect on the ability to drive vehicles and work with mechanisms have not been carried out.
Cases of overdose with duloxetine alone or in combination with other preparations at a dose of 5400 mg have been reported. There have been reports of some deaths after an overdose of duloxetine, mainly in combination with other preparations, as well as duloxetine alone at a dose of about 1000 mg. Signs and symptoms of overdose (alone or in combination with other preparations) included drowsiness, coma, serotonin syndrome, seizures, vomiting, and tachycardia.
The most commonly reported adverse reactions in patients treated with duloxetine were nausea, headache, dry mouth, drowsiness, and dizziness. However, most of the common side effects were mild to moderate, they usually occurred at the beginning of treatment, most of them tended to disappear, even with prolonged therapy.
Due to the risk of serotonin syndrome, duloxetine should not be used in combination with nonselective irreversible IMAOs or within 14 days after the end of their use. Based on the half-life of duloxetine, MAOIs should be started no earlier than 5 days after stopping duloxetine.
Keep out of the reach of children in the original packaging at a temperature not exceeding 30 ° C.
Shelf life is 2 years.
There are no reviews for this product.